Anika Therapeutics, Inc. 10-Q

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS   Issuer Purchases of Equity Securities   On May 2, 2019, we announced that our Board of Directors approved a $50.0 million share repurchase program with $30.0 million to be utilized for an accelerated share repurchase program, which was completed in January 2020, and $20.0 million reserved for open market repurchases which represents the maximum value of shares that may yet be purchased. No open market repurchases were made during the six-month period ended June 30, 2022.   ITEM 6. EXHIBITS   Exhibit   No.           †10.1 Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan (as amended effective June 8, 2022) (incorporated by reference to Exhibit 99.1 to the Current Report on Form 8-K filed on June 10, 2022)       (31) Rule 13a-14(a)/15d-14(a) Certifications       *31.1 Certification of Dr. Cheryl R. Blanchard, pursuant to Rules   13a-15(e)   and 15d-15(e), as adopted pursuant to Section   302 of the Sarbanes-Oxley Act of 2002.       *31.2 Certification of Michael Levitz, pursuant to Rules   13a-15(e)   and 15d-15(e), as adopted pursuant to Section   302 of the Sarbanes-Oxley Act of 2002.       (32) Section 1350 Certifications       **32.1 Certification of Dr. Cheryl R. Blanchard, and Michael Levitz, pursuant to 18 U.S.C. Section   1350, as adopted pursuant to Section   906 of the Sarbanes-Oxley Act of 2002.       (101) XBRL       *101 The following materials from Anika Therapeutics, Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 as filed with the SEC on August 4, 2022, formatted in Inline XBRL (eXtensible Business Reporting Language), as follows:         i. Consolidated Balance Sheets as of June 30, 2022 (unaudited) and December 31, 2021 (unaudited)   ii. Consolidated Statements of Operations and Comprehensive Income for the Three and Six Months Ended June 30, 2022 and June 30, 2021 (unaudited)   iii. Consolidated Statements of Stockholders’ Equity for the Six Months Ended June 30, 2022 and June 30, 20201(unaudited)   iv. Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2022 and June 30, 2021 (unaudited)   v. Notes to Consolidated Financial Statements (unaudited)     104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)      * Filed herewith. ** Furnished herewith. † Management contract or compensatory plan or arrangement.   31     SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.       ANIKA THERAPEUTICS, INC.         Date: August 4, 2022 By: /s/ MICHAEL LEVITZ       Michael Levitz       Executive Vice President, Chief Financial Officer and Treasurer     (Authorized Officer and Principal Financial Officer)                             32